Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

aspen pharma schweiz gmbh - melphalanum - compresse rivestite con film - melphalanum 2 mg, cellulosum microcristallinum, crospovidonum, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, macrogolum 400, e 171, pro compresso obducto. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

aspen pharma schweiz gmbh - melphalanum - pulver und lösungsmittel zur herstellung einer injektions-/infusionslösung - praeparatio cryodesiccata: melphalanum 50 mg, povidonum k 12, acidum hydrochloridum pro vitro. solvens: natrii citras dihydricus corresp. natrium 46.9 mg, propylenglycolum, ethanolum 96 per centum 0.52 ml, aqua ad iniectabile q.s. ad solutionem pro 10 ml. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

ideogen ag - melphalanum - pulver und lösungsmittel zur herstellung einer injektions-/infusionslösung - pulver: melphalanum 50 mg ut melphalani hydrochloridum, povidonum, acidum hydrochloridum, pro vitro. solvens: natrii citras dihydricus corresp. natrium 53.4 mg, propylenglycolum 6214.8 mg, ethanolum 96 per centum 424.3 mg, aqua ad iniectabile q.s. ad solutionem pro 10 ml. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

adienne sa - melphalanum - polvere e solvente per concentrato per soluzione per infusione - melphalanum 50 mg ut melphalani hydrochloridum, povidonum k 12, acidum hydrochloridum, pro vitro. solvens: natrii citras dihydricus corresp. natrium 15.63 mg, propylenglycolum 6 ml, ethanolum 96 per centum 0.52 ml, aqua ad iniectabile, q.s. ad solutionem pro 10 ml. - citostatico - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

adienne sa - melphalanum - polvere e solvente per concentrato per soluzione per infusione - melphalanum 200 mg ut melphalani hydrochloridum, povidonum k 12, acidum hydrochloridum, pro vitro. solvens: natrii citras dihydricus corresp. natrium 62.52 mg, propylenglycolum 24 ml, ethanolum 96 per centum 2.08 ml, aqua ad iniectabile, q.s. ad solutionem pro 40 ml. - citostatico - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - agenti antineoplastici - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Unione Europea - italiano - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - mieloma multiplo - agenti antineoplastici - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sun pharmaceutical industries (europe) b.v. - melfalan - melfalan